The NHS is embarking on a groundbreaking trial of a new device designed to assist the estimated eight million individuals in the UK suffering from sleep apnoea, a condition that causes intermittent breathing interruptions during sleep. This innovative device offers hope for those who struggle with traditional treatments, as it avoids the discomfort often associated with existing options.
Understanding Sleep Apnoea
Sleep apnoea is a chronic disorder characterised by repeated pauses in breathing, often due to airway obstructions. These interruptions can lead to severe daytime fatigue, difficulty concentrating, and an elevated risk of serious health issues, including cardiovascular diseases and accidents in both workplace and road settings.
Although continuous positive airway pressure (CPAP) machines are regarded as the standard treatment, adherence remains a significant challenge. Research indicates that over half of patients discontinue CPAP therapy within a year, often due to its intrusive nature and discomfort.
The Zeus Sleep Device
The new device, known as the “Zeus Sleep device,” presents a non-invasive alternative. Worn discreetly beneath the chin, it does not rely on face masks or mouthpieces. Instead, it utilises gentle electrical stimulation to keep the airway open by preventing the relaxation of the tongue and throat muscles during sleep.
Experts at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London will oversee the trial, which is anticipated to commence this summer. Professor Joerg Steier, a specialist in respiratory and sleep medicine at King’s College London, emphasised the potential benefits of this device, stating, “With the treatment for sleep apnoea, we have an effect on overall mortality and cardiovascular mortality.”
The Implications of Untreated Sleep Apnoea
If sleep apnoea remains untreated, the long-term consequences can be dire. Chronic fatigue is just the beginning; the condition may also lead to high blood pressure, stroke, heart disease, and type 2 diabetes. Professor Steier explained that as breathing ceases during sleep, oxygen levels drop, prompting the heart to work harder to circulate oxygen.
This cycle not only fragments sleep but can also result in heightened stress levels and increased heart rate, further complicating the health of individuals with this disorder. As obesity rates rise, so too does the prevalence of sleep apnoea, as excess weight can constrict the airway.
A Promising Future for Treatment
The Zeus device, described by Professor Steier as “hardly visible,” resembles a small patch and is significantly less cumbersome than a CPAP machine. While permanent implantable devices exist, their cost—often exceeding £20,000—limits accessibility. In contrast, the Zeus device is priced at approximately £250, making it a more feasible option for many patients.
The National Institute for Health and Care Research has allocated £1.48 million in public funding to support the trial, which aims to recruit around 200 participants across seven NHS regions in the UK. Previous studies have shown encouraging results, with many users reporting improved sleep quality and increased daytime alertness.
Why it Matters
The introduction of the Zeus Sleep device could transform the landscape of sleep apnoea treatment in the UK. By offering a more comfortable and accessible alternative to traditional therapies, this device has the potential to improve the quality of life for millions. As the NHS continues to innovate in patient care, the outcomes of this trial may pave the way for broader acceptance and use of non-invasive sleep apnoea solutions, ultimately reducing the significant health risks associated with this condition.